K-bio leads platform tech exports, surpasses 18 trillion won this year Platform technologies propel record biotech exports as ...

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

The company said some patients had dropped out of the trial because they felt they were losing too much weight.

Lilly reports Phase 3 data showing retatrutide delivered substantial weight loss, reduced knee pain, and improved ...

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

Dec 9 (Reuters) - Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster ...

Eli Lilly said it plans to invest more than $6 billion in a new facility in Alabama to produce its experimental weight-loss pill.